Effect of Liraglutide on the Metabolic Profile in Patients With Type 2 Diabetes and Cardiovascular Disease

NCT04057261 on ClinicalTrials.gov · last registry update 2021-03-10

Withdrawn before anyone was enrolled. Its estimated completion date, August 2022, has passed with no update to the record. Primary outcome, as filed: Changes in the metabolomics profile (fold changes) between Liraglutide treatment group and placebo group after 1 and 3 months. A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. liraglutide is already approved in the US for cardiovascular disease and type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: WITHDRAWN
Phase: P3
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: RWTH Aachen University
Sponsor type: Other
Enrollment: 0
Started: 2020-11
Primary completion: 2022-08 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Changes in the metabolomics profile (fold changes) between Liraglutide treatment group and placebo group after 1 and 3 months

Conditions studied

Type 2 Diabetes · Cardiovascular Diseases

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.